Nuala Moran

It is time to drop euphemisms like DNA medicines and gene-based medicines. Gene therapy, says Nuala Moran, has made it through to the commercial mainstream.

As Science|Business launches its report on demand-driven innovation, we take a look how two universities are changing their structures in a bid to become innovation friendly.

Its government will increase science spending by 25 per cent in the next three years – but the UK won’t meet the 3 per cent Lisbon target.

A tale of two cities: as the industry in Lyon trumpeted the benefits of biotech, MEPs in Strasbourg looked the other way, and declined to debate them

The band of UK quoted tech commercialisation companies has another member. Ipso Ventures joined the AIM market, raising £4.5 million.

The UK’s two major public funders of stem cell research are to run a national public discussion about the controversial field of stem cell research.

The Drugs for Neglected Diseases initiative launched its first product, a new formulation of for treating malaria.

A new and fast-growing sector of the private equity market aims to fund companies that put sustainability at their heart. A first survey of the field shows how.

Venture capitalists are on a roll: in the past week two more firms confirmed the closing of significant new funds, to add to five others announced this year.

The UK’s system for pricing drugs is to move from one based on controlling profits to a value-based approach. The switch has implications for other countries in Europe.